Genscript Biotech Corp Class H GNNSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.53
- Day Range
- $1.50–1.50
- 52-Week Range
- $1.50–3.20
- Bid/Ask
- $1.30 / $1.46
- Market Cap
- $3.19 Bil
- Volume/Avg
- 28,290 / 14,452
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.77
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
GenScript Biotech is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. The company estimates that more than two-thirds of GenScript’s valuation is from its ownership stake in Legend.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6,937
- Website
- https://www.genscript.com
Comparables
Valuation
|
Metric
|
GNNSF
|
01244
|
APLM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.46 | 1.47 | 2.29 |
Price/Sales | 3.77 | 1.91 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GNNSF
01244
APLM
Financial Strength
|
Metric
|
GNNSF
|
01244
|
APLM
|
|---|---|---|---|
Quick Ratio | 4.50 | 2.54 | 2.82 |
Current Ratio | 4.76 | 2.67 | 2.95 |
Interest Coverage | −14.42 | −148.04 | −1,154.63 |
Quick Ratio
GNNSF
01244
APLM
Profitability
|
Metric
|
GNNSF
|
01244
|
APLM
|
|---|---|---|---|
Return on Assets (Normalized) | −9.60% | −16.32% | −123.31% |
Return on Equity (Normalized) | −25.81% | −24.03% | — |
Return on Invested Capital (Normalized) | −15.54% | −20.28% | — |
Return on Assets
GNNSF
01244
APLM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zpjcdhkjv | Hylqn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wkwnlnfw | Jppwgz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zgmfszmh | Zhnxqw | $99.5 Bil | |
MRNA
| Moderna Inc | Nbcpljr | Fzvq | $38.8 Bil | |
ARGX
| argenx SE ADR | Rgybxjxgc | Jyw | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Crtjqrr | Ssydw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sjchdbwl | Sgrflp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ktwftxbp | Pjnhlr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jfsyxxjss | Fyztsr | $12.5 Bil | |
INCY
| Incyte Corp | Ygwzqgqdb | Kxqrbv | $11.6 Bil |